Interpace Biosciences Inc. (IDXG)

[Renegades17]

I would worry about Q1 results

Jack spent the bulk of the quarter raising capital and negotiating his way out of the RedPath deal. Did he have enough focus to execute on the business and generate sales? Don't forget, Q4 wasn't very good either given a sharp deceleration in revenue growth.

He will book a gain on the resolution of the severance agreements with the former management team, so that will help some. That said, the benefit from that gain will be spread over 2x the number of shares than he had entering the quarter.

Personally, I would wait for Q1 results or perhaps start nibbling in the low $2s.